ClinicalTrials.gg
CompletedNCT01470612OCTAVEUpdated Sep 17, 2021Results posted

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

A Phase 3 interventional study of CP-690,550 and CP-690,550 in Ulcerative Colitis, sponsored by Pfizer. Completed at 252 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
944
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing tofacitinib in Colitis, Ulcerative — 3 open to participants now, 6 under way, 1 of them phase 3. tofacitinib · Colitis, Ulcerative.

Enrollment
Largest of 14
944 · median 107
Started
2012
with 3 others
Phase 3
5 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
7 of 14
Pfizer

Among the 14 studies testing tofacitinib in Colitis, Ulcerative, this one has the largest enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 14 studies testing tofacitinib in Colitis, Ulcerative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tofacitinib in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study is an open label, long-term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of CP-690,550.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative colitis
  • open-label
  • long term treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who completed induction studies A3921094 or A3921095 and were classified as not meeting clinical response criteria; OR
  • Subjects who completed maintenance study A3921096 or who discontinued treatment early in Study A3921096 due to treatment failure.

Exclusion criteria

Exclusion Criteria:

  • Subjects who had a major protocol violation in Study A3921094, A3921095 or A3921096.
  • Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.
  • Subjects who have had surgery for ulcerative colitis or in the opinion of the investigator, are likely to require surgery for ulcerative colitis during the study period.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
944 participants (actual)

Study arms

  • Experimental
    CP-690,550 5 mg BID

    5 mg BID

    Drug: CP-690,550

  • Experimental
    CP-690,550 10 mg BID

    10 mg BID

    Drug: CP-690,550

Interventions

  • 5 mg tablets, BID, for at least 12 months

  • 10 mg tablets, BID, for at least 12 months

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.

    Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)

  2. Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs)

    Serious infections were treated infections that required parenteral antimicrobial therapy or hospitalization for treatment or; met other criteria that required the infection to be classified as a serious adverse event (SAE). SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)

  3. Number of Participants With Laboratory Test Abnormalities

    Laboratory abnormalities: Hemoglobin, hematocrit, RBC: \<0.8\* LLN; reticulocytes (absolute \[Abs\], %): \<0.5\* LLN, \>1.5\* ULN; MCV, MCH: \<0.9\* LLN, \>1.1\* ULN; platelets:\<0.5\* LLN, \>1.75\* ULN; WBC:\<0.6\* LLN,\>1.5\* ULN; lymphocytes (Abs, %), total neutrophils (Abs,%):\<0.8\* LLN, \>1.2\* ULN; Basophils (Abs,%),eosinophils(Abs, %),monocytes(Abs, %):\>1.2\* ULN; total bilirubin,direct bilirubin,indirect bilirubin:\>1.5\* ULN; AST,ALT,gamma GT, LDH,ALP: \>3.0\* ULN; total protein,albumin: \<0.8\* LLN,\>1.2\* ULN: BUN,creatinine: \>1.3\* ULN;uric acid:\>1.2\* ULN; cholesterol,triglycerides: \>1.3\* ULN; cholesterol (HDL: \<0.8\* LLN; LDL: \>1.2\* ULN); sodium: \<0.95\* LLN, \>1.05\* ULN; potassium, chloride, calcium, bicarbonate: \<0.9\* LLN, \>1.1\* ULN; glucose: \<0.6\* LLN; creatine kinase \>2.0\* ULN; urine specific gravity: \<1.003; urine pH: \<4.5; urine (glucose,protein,blood,nitrite,leukocyte,esterase): \>=1; Urine (RBC,WBC): \>=20; urine epithelial cells:\>=6; urine (casts,granular casts,hyaline casts): \>1; urine bacteria:\>20.

    Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)

  4. Number of Participants With Vital Sign Abnormalities

    Vital sign abnormalities included greater than or equal to (\>=) 30 millimeter of mercury \[mmHg\] increase in systolic blood pressure (BP), \>=30 mmHg decrease in systolic BP, Systolic BP (less than \[\<\] 90 mmHg), \>=20 mmHg increase in diastolic BP, \>=20 mmHg decrease in diastolic BP, diastolic BP (\<50 mmHg), pulse rate (\<40 beats per minute \[BPM\]), pulse rate (greater than \[\>\] 120 BPM).

    Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)

  5. Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline

    Physical examinations included weight, general appearance, head, ears, eyes, nose, mouth, throat, thyroid, skin (presence of rash), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs, peripheral edema), abdominal (palpation and auscultation), perianal, musculoskeletal, extremities, neurologic (mental status, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Clinically significant changes were judged by the investigator.

    Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)

  6. Number of Participants With Electrocardiogram (ECG) Abnormalities

    ECG abnormalities criteria: maximum PR interval (\>=300 millisecond); maximum QRS complex (\>=200 millisecond); and maximum QT interval (\>=500 millisecond).

    Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)

  7. Incidence Rates for Adjudicated Cardiovascular, Malignancy, Opportunistic Infections and Thromboembolic Safety Events

    Incidence rates for adjudicated cardiovascular (major adverse cardiovascular event \[MACE\]), malignancy (non-melanoma skin cancer \[NMSC\], malignancies excluding NMSC, opportunistic infections (OIs) (both herpes zoster and non herpes zoster OIs) and thromboembolic (venous thromboembolism) safety events were analyzed. This outcome measure was measured in participants with events per 100 participants-years (pt with events/100 pts-yrs).

    Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)

Secondary outcomes

  1. Number of Participants in Remission at Months 2, 12, 24 and 36: Observed Cases

    Remission in participants was defined as a total Mayo score of less than or equals to (\<=) 2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and physician global assessment (PGA), each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.

    Time frame: Months 2, 12, 24 and 36

  2. Number of Participants in Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

    Remission in participants was defined as a total Mayo score of \<=2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.

    Time frame: Months 2, 12, 24 and 36

  3. Number of Participants in Clinical Remission at Months 2, 12, 24 and 36: Observed Cases

    Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.

    Time frame: Months 2, 12, 24 and 36

  4. Number of Participants in Clinical Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

    Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.

    Time frame: Months 2, 12, 24 and 36

  5. Number of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Observed Cases

    PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.

    Time frame: Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84

  6. Number of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

    PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total PMS score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.

    Time frame: Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84

  7. Number of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Observed Cases

    Mucosal healing in participants was defined as Mayo endoscopic sub score of 0 or 1. The Mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicated higher disease severity.

    Time frame: Months 2, 12, 24 and 36

  8. Number of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

    Mucosal healing in participants was defined as mayo endoscopic sub score of 0 or 1. The mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicating higher disease severity.

    Time frame: Months 2, 12, 24 and 36

  9. Number of Participants With Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score >=170 at Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

    IBDQ was a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease-specific quality of life in participants with inflammatory bowel disease (IBD), including ulcerative colitis consisted of 32 items scored from 1 (worst response) to 7 (best response). For each domain, higher score indicates better quality of life (QOL). Total IBDQ score was the sum of each item score, and ranged from 32 to 224 with a higher score indicated better QOL.

    Time frame: Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84

07

Results

Posted Sep 17, 2021

Participant flow

Participants enrolled in this Study A3921139: 1) who had completed or had early withdrawal due to treatment failure in Study A3921096 (NCT01458574) 2) or who were non-responders after completing induction studies A3921094 (NCT01465763) or A3921095 (NCT01458951). Eligible participants assigned to either Tofacitinib 5 mg BID or 10 mg BID depending if participant was in remission at baseline of A3921139. Remission=total Mayo score \<=2 with no individual sub score \>1, rectal bleeding sub score =0.

Participant flow — Overall Study
MilestoneTofacitinib 5 mg BIDTofacitinib 10 mg BID
Started175769
Completed91104
Not completed84665
Withdrew: Adverse event2080
Withdrew: Death01
Withdrew: Lack of efficacy20326
Withdrew: Lost to follow-up25
Withdrew: Did not meet entrance criteria01
Withdrew: Pregnancy210
Withdrew: Protocol violation27
Withdrew: Withdrawal by subject2479
Withdrew: Other14156

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.

Time frame:
Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Participants with AEs154626
Participants with SAEs39147
PrimaryNumber of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs)

Serious infections were treated infections that required parenteral antimicrobial therapy or hospitalization for treatment or; met other criteria that required the infection to be classified as a serious adverse event (SAE). SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Reported as:
Count of participants · Participants
Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs)
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs)831
PrimaryNumber of Participants With Laboratory Test Abnormalities

Laboratory abnormalities: Hemoglobin, hematocrit, RBC: \<0.8\* LLN; reticulocytes (absolute \[Abs\], %): \<0.5\* LLN, \>1.5\* ULN; MCV, MCH: \<0.9\* LLN, \>1.1\* ULN; platelets:\<0.5\* LLN, \>1.75\* ULN; WBC:\<0.6\* LLN,\>1.5\* ULN; lymphocytes (Abs, %), total neutrophils (Abs,%):\<0.8\* LLN, \>1.2\* ULN; Basophils (Abs,%),eosinophils(Abs, %),monocytes(Abs, %):\>1.2\* ULN; total bilirubin,direct bilirubin,indirect bilirubin:\>1.5\* ULN; AST,ALT,gamma GT, LDH,ALP: \>3.0\* ULN; total protein,albumin: \<0.8\* LLN,\>1.2\* ULN: BUN,creatinine: \>1.3\* ULN;uric acid:\>1.2\* ULN; cholesterol,triglycerides: \>1.3\* ULN; cholesterol (HDL: \<0.8\* LLN; LDL: \>1.2\* ULN); sodium: \<0.95\* LLN, \>1.05\* ULN; potassium, chloride, calcium, bicarbonate: \<0.9\* LLN, \>1.1\* ULN; glucose: \<0.6\* LLN; creatine kinase \>2.0\* ULN; urine specific gravity: \<1.003; urine pH: \<4.5; urine (glucose,protein,blood,nitrite,leukocyte,esterase): \>=1; Urine (RBC,WBC): \>=20; urine epithelial cells:\>=6; urine (casts,granular casts,hyaline casts): \>1; urine bacteria:\>20.

Time frame:
Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Number of Participants With Laboratory Test Abnormalities162670
PrimaryNumber of Participants With Vital Sign Abnormalities

Vital sign abnormalities included greater than or equal to (\>=) 30 millimeter of mercury \[mmHg\] increase in systolic blood pressure (BP), \>=30 mmHg decrease in systolic BP, Systolic BP (less than \[\<\] 90 mmHg), \>=20 mmHg increase in diastolic BP, \>=20 mmHg decrease in diastolic BP, diastolic BP (\<50 mmHg), pulse rate (\<40 beats per minute \[BPM\]), pulse rate (greater than \[\>\] 120 BPM).

Time frame:
Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Abnormalities
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Systolic BP (>=30 mmHg increase)20113
Systolic BP (>=30 mmHg decrease)1944
Systolic BP (<90 mmHg)313
Diastolic BP (>=20 mmHg increase)21137
Diastolic BP (>=20 mmHg decrease)3778
Diastolic BP (<50 mmHg)316
Pulse Rate (<40 BPM)10
Pulse Rate (>120 BPM)08
PrimaryNumber of Participants With Clinically Significant Changes in Physical Examinations From Baseline

Physical examinations included weight, general appearance, head, ears, eyes, nose, mouth, throat, thyroid, skin (presence of rash), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs, peripheral edema), abdominal (palpation and auscultation), perianal, musculoskeletal, extremities, neurologic (mental status, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Clinically significant changes were judged by the investigator.

Time frame:
Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline84391
PrimaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

ECG abnormalities criteria: maximum PR interval (\>=300 millisecond); maximum QRS complex (\>=200 millisecond); and maximum QT interval (\>=500 millisecond).

Time frame:
Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Maximum PR interval (>=300)00
Maximum QRS complex (>=200)00
Maximum QT interval (>=500)00
PrimaryIncidence Rates for Adjudicated Cardiovascular, Malignancy, Opportunistic Infections and Thromboembolic Safety Events

Incidence rates for adjudicated cardiovascular (major adverse cardiovascular event \[MACE\]), malignancy (non-melanoma skin cancer \[NMSC\], malignancies excluding NMSC, opportunistic infections (OIs) (both herpes zoster and non herpes zoster OIs) and thromboembolic (venous thromboembolism) safety events were analyzed. This outcome measure was measured in participants with events per 100 participants-years (pt with events/100 pts-yrs).

Time frame:
Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Reported as:
Number · pt with events/100 pts-yrs
Incidence Rates for Adjudicated Cardiovascular, Malignancy, Opportunistic Infections and Thromboembolic Safety Events
pt with events/100 pts-yrsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Major adverse cardiovascular event (MACE)0.31 (0.04 to 1.13)0.11 (0.01 to 0.40)
Nonmelanoma skin cancer (NMSC)0.96 (0.35 to 2.08)0.68 (0.35 to 1.19)
Malignancies excluding NMSC1.09 (0.44 to 2.25)1.00 (0.60 to 1.59)
Herpes Zoster OI0.47 (0.10 to 1.37)0.79 (0.43 to 1.32)
Non Herpes Zoster OIs0.16 (0.00 to 0.87)0.17 (0.03 to 0.49)
Venous thromboembolism0.00 (0.00 to 0.57)0.33 (0.12 to 0.73)
SecondaryNumber of Participants in Remission at Months 2, 12, 24 and 36: Observed Cases

Remission in participants was defined as a total Mayo score of less than or equals to (\<=) 2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and physician global assessment (PGA), each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.

Time frame:
Months 2, 12, 24 and 36
Reported as:
Count of participants · Participants
Number of Participants in Remission at Months 2, 12, 24 and 36: Observed Cases
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 2131188
Month 12129279
Month 24103264
Month 3698239
SecondaryNumber of Participants in Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

Remission in participants was defined as a total Mayo score of \<=2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.

Time frame:
Months 2, 12, 24 and 36
Reported as:
Count of participants · Participants
Number of Participants in Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 2131188
Month 12129279
Month 24103264
Month 36103259
SecondaryNumber of Participants in Clinical Remission at Months 2, 12, 24 and 36: Observed Cases

Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.

Time frame:
Months 2, 12, 24 and 36
Reported as:
Count of participants · Participants
Number of Participants in Clinical Remission at Months 2, 12, 24 and 36: Observed Cases
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 2132191
Month 12129282
Month 24104266
Month 36102240
SecondaryNumber of Participants in Clinical Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.

Time frame:
Months 2, 12, 24 and 36
Reported as:
Count of participants · Participants
Number of Participants in Clinical Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 2132191
Month 12129282
Month 24104266
Month 36107260
SecondaryNumber of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Observed Cases

PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.

Time frame:
Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84
Reported as:
Count of participants · Participants
Number of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Observed Cases
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 1158275
Month 4152375
Month 6155395
Month 9154390
Month 15139361
Month 18137354
Month 21125351
Month 27117319
Month 30117307
Month 33111304
Month 39102261
Month 4295236
Month 4595212
Month 4887183
Month 5187162
Month 5468140
Month 5754120
Month 603898
Month 632880
Month 661967
Month 691049
Month 72640
Month 75324
Month 78418
Month 81—10
Month 84—6
SecondaryNumber of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total PMS score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.

Time frame:
Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84
Reported as:
Count of participants · Participants
Number of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 1158275
Month 4152375
Month 6155395
Month 9154390
Month 15139361
Month 18137354
Month 21125351
Month 27117325
Month 30117316
Month 33114317
Month 39108293
Month 42102286
Month 45102283
Month 4895274
Month 5196267
Month 5476250
Month 5761234
Month 6044213
Month 6331194
Month 6622168
Month 6913131
Month 727102
Month 75373
Month 78452
Month 81029
Month 84015
SecondaryNumber of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Observed Cases

Mucosal healing in participants was defined as Mayo endoscopic sub score of 0 or 1. The Mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicated higher disease severity.

Time frame:
Months 2, 12, 24 and 36
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Observed Cases
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 2152279
Month 12140340
Month 24119307
Month 36107265
SecondaryNumber of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

Mucosal healing in participants was defined as mayo endoscopic sub score of 0 or 1. The mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicating higher disease severity.

Time frame:
Months 2, 12, 24 and 36
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 2152279
Month 12140340
Month 24119307
Month 36113285
SecondaryNumber of Participants With Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score >=170 at Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)

IBDQ was a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease-specific quality of life in participants with inflammatory bowel disease (IBD), including ulcerative colitis consisted of 32 items scored from 1 (worst response) to 7 (best response). For each domain, higher score indicates better quality of life (QOL). Total IBDQ score was the sum of each item score, and ranged from 32 to 224 with a higher score indicated better QOL.

Time frame:
Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84
Reported as:
Count of participants · Participants
Number of Participants With Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score >=170 at Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Month 2154419
Month 6151395
Month 12140365
Month 18123354
Month 24120315
Month 30115299
Month 36111294
Month 4893265
Month 6045215
Month 72899
Month 84014

Adverse events

Collected over Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 5 mg BID0/175 (0%)39/175 (22.3%)134/175 (76.6%)
Tofacitinib 10 mg BID6/769 (0.8%)147/769 (19.1%)550/769 (71.5%)
Most frequent serious events
Showing 10 of 168
Most frequent serious events
EventTofacitinib 5 mg BIDTofacitinib 10 mg BID
Colitis ulcerativeGastrointestinal disorders4/17538/769
Foot fractureInjury, poisoning and procedural complications2/1750/769
Ligament ruptureInjury, poisoning and procedural complications2/1750/769
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1752/769
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1750/769
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1755/769
Acute myocardial infarctionCardiac disorders1/1750/769
Angina pectorisCardiac disorders1/1752/769
Atrial fibrillationCardiac disorders1/1750/769
Cardiac failureCardiac disorders1/1750/769
Most frequent other events
Showing 10 of 59
Most frequent other events
EventTofacitinib 5 mg BIDTofacitinib 10 mg BID
Colitis ulcerativeGastrointestinal disorders44/175131/769
NasopharyngitisInfections and infestations41/175157/769
InfluenzaInfections and infestations23/17563/769
Blood creatine phosphokinase increasedInvestigations19/17585/769
Upper respiratory tract infectionInfections and infestations19/17577/769
ArthralgiaMusculoskeletal and connective tissue disorders17/17576/769
BronchitisInfections and infestations17/17530/769
HypertensionVascular disorders17/17528/769
CoughRespiratory, thoracic and mediastinal disorders14/17538/769
Urinary tract infectionInfections and infestations13/17534/769

Baseline characteristics

Full analysis set (FAS) included all participants who received at least 1 dose of study medication in this study.

Age, Continuous
Age, Continuous(years)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTotal
Mean44.5 ± 14.640.5 ± 13.541.2 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTotal
Female79310389
Male96459555
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTotal
White136615751
Black099
Asian2597122
Other92433
Unspecified52429
08

Study locations

252 sites
  • Alabama Medical Group, P.C.
    Mobile, Alabama 36608, United States
  • Desert Sun Clinical Research, LLC
    Tucson, Arizona 85710, United States
  • Desert Sun Gastroenterology
    Tucson, Arizona 85710, United States
  • Desert Sun Surgery Center
    Tucson, Arizona 85710, United States
  • Altman Clinical and Translational Research Institute
    La Jolla, California 92037-0897, United States
  • Perlman Medical Offices - UC San Diego Health System
    La Jolla, California 92037, United States
  • UCSD Medical Center
    La Jolla, California 92093, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Cedars Sinai Surgery Center
    Los Angeles, California 90048, United States
  • Alliance Clinical Research
    Oceanside, California 92056, United States
  • Center for Endoscopy- Covenant Surgical Partners
    Oceanside, California 92056, United States
  • Sharp Rees-Stealy Medical Group, Inc.
    San Diego, California 92101, United States
  • Clinical Applications Laboratories, Inc
    San Diego, California 92103, United States
  • Sharp Rees-Stealy Medical Group
    San Diego, California 92123, United States
  • UCSF Center for Colitis and Crohn's Disease
    San Francisco, California 94115, United States
  • Connecticut Clinical Research Institute
    Bristol, Connecticut 06010, United States
  • Endoscopy Center of Connecticut, LLC
    Guilford, Connecticut 06437, United States
  • Endoscopy Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Gastroenterology Center of Connecticut, PC
    Hamden, Connecticut 06518, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • North Florida Gastroenterology Research, LLC
    Orange Park, Florida 32073, United States
  • Citrus Ambulatory Surgery Center
    Orlando, Florida 32806, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Advanced Gastroenterology Center
    Port Orange, Florida 32127, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Endoscopy Center
    Port Orange, Florida 32127, United States
  • Port Orange Urgent Care
    Port Orange, Florida 32127, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 30024, United States
  • Cotton O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • Digestive Disease Associates, PA
    Catonsville, Maryland 21228, United States
  • Gastrointestinal Diagnostic Center
    Catonsville, Maryland 21228, United States
  • MGG Group Co., Inc., Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Howard County GIDC
    Columbia, Maryland 21044, United States
  • East Ann Arbor Health and Geriatrics Center -UMHS
    Ann Arbor, Michigan 48109-2701, United States
  • Michigan Clinical Research Unit - UMHS
    Ann Arbor, Michigan 48109-5872, United States
  • Medical Science Research Building 1 - UMHS
    Ann Arbor, Michigan 48109, United States
  • University of Michigan Health Systems
    Ann Arbor, Michigan 48109, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Surgical Centers of Michigan
    Troy, Michigan 48098, United States
  • Huron Gastroenterology Associates - Center for Digestive Care
    Ypsilanti, Michigan 48197, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • AGA Clinical Research Associates, LLC
    Egg Harbor Township, New Jersey 08234, United States
  • South Jersey Gastroenterology, P.A.
    Marlton, New Jersey 08053, United States
  • The Gastroenterology Group of South Jersey
    Vineland, New Jersey 08360, United States
  • NYU Langone Long Island Clinical Research Associates
    Lake Success, New York 11042, United States
  • IBD Center - The Mount Sinai Hospital
    New York, New York 10029, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Kornbluth, Legnani, George MD, PC
    New York, New York 10128, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Carolina Research, Carolina Digestive Diseases
    Greenville, North Carolina 27834, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Great Lakes Gastroenterology Research, LLC
    Mentor, Ohio 44060, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1375, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • Baylor College of Medicine- Baylor Medical Center
    Houston, Texas 77030, United States
  • McGovern Medical School -The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Memorial Hermann Hospital
    Houston, Texas 77030, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • Alpine Medical Group
    Salt Lake City, Utah 84102, United States
  • Salt Lake Regional Hospital
    Salt Lake City, Utah 84102, United States
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
  • VCU Health System Digestive Health Center
    Richmond, Virginia 23298, United States
  • VCU Health System Endoscopy Suite
    Richmond, Virginia 23298, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Center for Digestive Health
    Milwaukee, Wisconsin 53215, United States
  • Wisconsin Center for Advanced Research - a division of GI Associates, LLC
    Milwaukee, Wisconsin 53215, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Liverpool Hospital eastern Campus
    Liverpool, New South Wales 2170, Australia
  • Eastern Health, Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Gastroenterology and Hepatology Unit
    Clayton, Victoria 3168, Australia
  • Landeskrankenhaus Innsbruck
    Innsbruck, 6020, Austria
  • Krankenhaus Barmherzige Brueder St. Veit/Glan
    St. Veit an der Glan, 9300, Austria
  • AKH Wien, Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • GZA St Vincentius
    Antwerpen, 2018, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven (University Hospital Leuven), Campus Gasthuisberg
    Leuven, 3000, Belgium
  • H-Hartziekenhuis Roeselare-Menen vzw
    Roeselare, 8800, Belgium
  • Hospital de Clinicas de Porto Alegre - HCPA
    Porto Alegre, RIO Grande DO SUL 90035-003, Brazil
  • University of Calgary, Heritage Medical Research Clinic, TRW Building
    Calgary, Alberta T2N 4Z6, Canada
  • University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre
    Edmonton, Alberta T6G 2B7, Canada
  • University of Alberta - Zeidler Ledcor Centre
    Edmonton, Alberta T6G 2X8, Canada
  • McMaster University Medical Center
    Hamilton, Ontario L8N 3Z5, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Hopital Maisonneuve-Rosemont/Pavillon Rachel-Tourigny
    Montreal, Quebec H1T 2M4, Canada
  • Montreal General Hospital - McGill University Health Care Centre
    Montreal, Quebec H3G 1A4, Canada
  • Saskatoon City Hospital
    Saskatoon, Saskatchewan S7K 0M7, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Instituto de Coloproctologia ICO S.A.S.
    Medellin, Antioquia 00000, Colombia

Showing the first 100 of 252 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, Sawyerr G, Shi H, Su C, Judd DT, Jones T, Loftus EV. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084. PubMed 36342120 ↗
  • Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient. 2023 Mar;16(2):95-103. doi: 10.1007/s40271-022-00603-w. Epub 2022 Nov 7. PubMed 36336750 ↗
  • Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panes J, Rubin DT. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis. 2023 Sep 1;29(9):1370-1379. doi: 10.1093/ibd/izac222. PubMed 36242764 ↗
  • Winthrop KL, Vermeire S, Long MD, Panes J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2023 Jan 5;29(1):85-96. doi: 10.1093/ibd/izac063. PubMed 35648151 ↗
  • Dubinsky MC, Magro F, Steinwurz F, Hudesman DP, Kinnucan JA, Ungaro RC, Neurath MF, Kulisek N, Paulissen J, Su C, Ponce de Leon D, Regueiro M. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023 Jan 5;29(1):51-61. doi: 10.1093/ibd/izac061. PubMed 35380664 ↗
  • Feagan BG, Khanna R, Sandborn WJ, Vermeire S, Reinisch W, Su C, Salese L, Fan H, Paulissen J, Woodworth DA, Niezychowski W, Sands BE. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1442-1453. doi: 10.1111/apt.16626. Epub 2021 Oct 6. PubMed 34614208 ↗
  • Panes J, Vermeire S, Dubinsky MC, Loftus EV, Lawendy N, Wang W, Salese L, Su C, Modesto I, Guo X, Colombel JF. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. J Crohns Colitis. 2021 Nov 8;15(11):1852-1863. doi: 10.1093/ecco-jcc/jjab065. PubMed 33884415 ↗
  • Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022 Mar;20(3):591-601.e8. doi: 10.1016/j.cgh.2021.02.043. Epub 2021 Mar 6. PubMed 33684552 ↗
  • Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan(R) Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis. 2021 Aug 19;27(9):1394-1408. doi: 10.1093/ibd/izaa289. PubMed 33324993 ↗
  • Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1821-1830.e3. doi: 10.1016/j.cgh.2020.10.038. Epub 2020 Oct 27. PubMed 33127596 ↗
  • Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):116-125.e5. doi: 10.1016/j.cgh.2020.10.004. Epub 2020 Oct 9. PubMed 33039585 ↗
  • Sands BE, Colombel JF, Ha C, Farnier M, Armuzzi A, Quirk D, Friedman GS, Kwok K, Salese L, Su C, Taub PR. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. Inflamm Bowel Dis. 2021 May 17;27(6):797-808. doi: 10.1093/ibd/izaa227. PubMed 32870265 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panes J. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2021 May 17;27(6):816-825. doi: 10.1093/ibd/izaa199. PubMed 32766762 ↗
  • Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panes J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2020 Jan;51(2):271-280. doi: 10.1111/apt.15555. Epub 2019 Oct 29. PubMed 31660640 ↗
  • Sandborn WJ, Panes J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9. PubMed 31599001 ↗
  • Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Jan;18(1):123-132.e3. doi: 10.1016/j.cgh.2019.04.059. Epub 2019 May 8. PubMed 31077827 ↗
  • Sandborn WJ, Panes J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23. PubMed 30476584 ↗
  • Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265. doi: 10.1093/ibd/izy131. PubMed 29850873 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Aug 2020, 94 months.

Results were first posted in Sep 2021, 1 year 1 month after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 94 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2011
First posted
Nov 11, 2011
StartActual
Oct 1, 2012
Primary completionActual
Aug 6, 2020
CompletionActual
Aug 6, 2020
Results first posted
Sep 17, 2021
Last update
Sep 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01470612
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 11, 2011
Start date
Oct 1, 2012
Primary completion
Aug 6, 2020
Completion
Aug 6, 2020
Results posted
Sep 17, 2021
Last update
Sep 17, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion